22/12/2014 20:33:43 Free Membership Login

Electro Optical Sciences News (NASDAQ:MELA)

DateTimeSource
Headline
07/03/20148:00AMGLOBEMELA Sciences Announces Pending One-for-Ten Reverse Stock Split
IRVINGTON, N.Y., July 3, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that its board of directors has approved a one-for-ten... More...>>
06/03/20148:00AMGLOBEMELA Sciences Initiates First Study to Investigate Real-World Clinical Impact of the MelaFind System on Melanoma Biopsy Decis...
IRVINGTON, N.Y., June 3, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, today announced that it has initiated a study to examine... More...>>
05/13/20144:01PMMWUSMELA Sciences Reports Its First Quarter 2014 Business and Financial Results
MELA Sciences Reports Its First Quarter 2014 Business and Financial Results Company to Host Conference Call Today at 4:30PM Eastern Time IRVINGTON, NY--(Marketwired - May 13, 2014) - MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the United States... More...>>
05/08/20148:37AMMWUSMELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma
MELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma IRVINGTON, NY--(Marketwired - May 8, 2014) - MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist... More...>>
05/07/20145:23PMMWUSMelanoma Diagnostic Developer, MELA Sciences, Hosts Q1 Conference Call Tuesday, May 13th at 4:30 pm ET
Melanoma Diagnostic Developer, MELA Sciences, Hosts Q1 Conference Call Tuesday, May 13th at 4:30 pm ET IRVINGTON, NY--(Marketwired - May 7, 2014) - MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists... More...>>
04/30/20148:37AMBWMELA Sciences Secures Final Investigative Site & Enrolls 100+ Patients for Post-Approval Study for MelaFind® System Optical ...
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind® system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced that it has concluded an agreement with the sixth and final investigative site participating in the Company’s post-approval study (PAS... More...>>
04/09/20148:23AMBWMedical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind® system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, appointed veteran healthcare executive Robert W. Cook as Chief Financial Officer, filling the position which had been vacant since December 31, 2013... More...>>
03/17/20144:00PMBWMELA Sciences Announces 2013 Fourth Quarter and Year-End Financial Results
MELA Sciences, Inc. (NASDAQ:MELA), (the “Company”), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced financial results for the fourth quarter and year ended December 31, 2013. Conference Call The Company will host a conference... More...>>
03/14/20147:55AMBWOptical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, as Director
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the appointment of veteran medical device investment banker Samuel E. Navarro to the Board of Directors. Mr. Navarro’s appointment brings MELA’s Board... More...>>
03/11/201410:35AMMWUSMELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41
MELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41 WEST HARRISON, NY--(Marketwired - Mar 11, 2014) - Fine tuning the crusade by MELA Sciences, Inc. (NASDAQ: MELA) to identify deadly melanoma earlier is featured in the March 10, 2014 issue of Flaherty... More...>>
03/06/20149:36AMBWDermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market’s close. MELA Sciences President and CEO, Rose Crane will host... More...>>
02/25/201411:03AMMWUSRose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Bus. Talk Radi...
Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM Interview at 1:05 pm CST / 2:05 pm EST on The Traders Network Radio Show, Hosted by Michael Yorba DALLAS, TX and IRVINGTON, NY--(Marketwired - Feb 25, 2014) - MELA Sciences, Inc. (NASDAQ:... More...>>
02/24/20147:55AMBWMelanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDAQ to fulfill the minimum $1.00 bid price requirement. The... More...>>
02/05/20145:15PMBWMELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common... More...>>
02/03/20147:55AMBWMelanoma Diagnostic Provider, MELA Sciences Provides Details of Recent $12.45 Million Private Placement
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from its recent Private Placement. Following is the text of the details relating to the private placement that... More...>>
01/31/20142:03PMBWCORRECTING & REPLACING Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Instituti...
Second graph, second sentence of release should read ...13,297,297 shares of common stock at an exercise price of $0.74. (sted ...11,714,286 shares of common stock at an exercise price of $0.74.). The corrected release reads: MELANOMA DIAGNOSTIC PROVIDER, MELA SCIENCES, TO RAISE $12.45 MILLION IN PRIVATE PLACEMENT TO INSTITUTIONAL... More...>>
01/31/20149:44AMBWMelanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors & MELA S...
MELA Sciences, Inc. (NASDAQ: MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45 million of the... More...>>
01/30/20147:55AMBWDermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
“This is the wave of the future for dermatology.” MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind® workshop during the 10th Annual Maui Derm Conference in Hawaii. The conference seeks... More...>>
01/27/20147:55AMBWMedical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC & to Exhibit at Maui Derm...
Presentation Audio and Slides Available Live and Via Webcast MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference... More...>>
01/22/20147:55AMBWMELA Sciences Announces the Results of its Third Clinical Advisory Meeting & the Four Clinical Posters Presented at the Winte...
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq mela141222 20:33